![JCM | Free Full-Text | Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review | HTML JCM | Free Full-Text | Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review | HTML](https://www.mdpi.com/jcm/jcm-10-00152/article_deploy/html/images/jcm-10-00152-g001.png)
JCM | Free Full-Text | Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review | HTML
![Denosumab (XGEVA): assessment from a pharmacist's perspective | European Journal of Hospital Pharmacy Denosumab (XGEVA): assessment from a pharmacist's perspective | European Journal of Hospital Pharmacy](https://ejhp.bmj.com/content/ejhpharm/21/3/175/F1.large.jpg)
Denosumab (XGEVA): assessment from a pharmacist's perspective | European Journal of Hospital Pharmacy
![Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications - ScienceDirect Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1525730415001667-gr6.jpg)
Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications - ScienceDirect
![Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications - ScienceDirect Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1525730415001667-gr1.jpg)
Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications - ScienceDirect
![PDF) Experience With Denosumab (XGEVA®) for Prevention of Skeletal-Related Events in the 10 Years After Approval PDF) Experience With Denosumab (XGEVA®) for Prevention of Skeletal-Related Events in the 10 Years After Approval](https://www.researchgate.net/publication/358420585/figure/fig2/AS:1130304261623808@1646496944402/Overview-of-A-normal-bone-physiology-B-tumor-pathology-and-C-the-mechanism-of_Q320.jpg)
PDF) Experience With Denosumab (XGEVA®) for Prevention of Skeletal-Related Events in the 10 Years After Approval
![THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis in: European Journal of Endocrinology Volume 179 Issue 1 (2018) THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis in: European Journal of Endocrinology Volume 179 Issue 1 (2018)](https://eje.bioscientifica.com/view/journals/eje/179/1/images/full-EJE-18-0056fig1.jpeg)
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis in: European Journal of Endocrinology Volume 179 Issue 1 (2018)
![Denosumab: mechanism of action and clinical outcomes - Hanley - 2012 - International Journal of Clinical Practice - Wiley Online Library Denosumab: mechanism of action and clinical outcomes - Hanley - 2012 - International Journal of Clinical Practice - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/1f5b0bc0-32e9-4e7e-a668-784d55e0870f/ijcp_12022_f2.gif)
Denosumab: mechanism of action and clinical outcomes - Hanley - 2012 - International Journal of Clinical Practice - Wiley Online Library
![The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review - ScienceDirect The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0305737217301809-gr2.jpg)
The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review - ScienceDirect
![Mechanism of action of denosumab compared to zoledronic acid. Notes:... | Download Scientific Diagram Mechanism of action of denosumab compared to zoledronic acid. Notes:... | Download Scientific Diagram](https://www.researchgate.net/profile/Andrew-Yee-7/publication/230850646/figure/fig1/AS:202882147196929@1425382281783/Mechanism-of-action-of-denosumab-compared-to-zoledronic-acid-Notes-RANKL-is-secreted-by.png)
Mechanism of action of denosumab compared to zoledronic acid. Notes:... | Download Scientific Diagram
![Bone health in breast cancer patients: A comprehensive statement by CECOG/SAKK Intergroup - The Breast Bone health in breast cancer patients: A comprehensive statement by CECOG/SAKK Intergroup - The Breast](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f04c01f7-6574-4868-8245-b995fcdb7188/gr3_lrg.jpg)
Bone health in breast cancer patients: A comprehensive statement by CECOG/SAKK Intergroup - The Breast
![Denosumab: mechanism of action and clinical outcomes - Hanley - 2012 - International Journal of Clinical Practice - Wiley Online Library Denosumab: mechanism of action and clinical outcomes - Hanley - 2012 - International Journal of Clinical Practice - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/7398e176-88ff-477a-9180-418cab6dba3d/ijcp_12022_f1.gif)